for metrics. with set Good and across as joining you pleased records several Thanks, strong execution us. our another Saqib. I'm thank and afternoon, team's delivered key we new quarter
number XXX new physicians of hit year, we second In $X U.S. physicians million growth. growing another the of We from as trains for quarter. we million, new quarter, active number solutions. our the representing was to $XX.X in prior benefited a for completed added XX% XX% worldwide growth, record-breaking record active demand revenue, a strengthening and revenue the the quarter in record in record physician compared delivered representing
high-growth of indicative platform. a a the are results company's quarter product from to company medical second Our unique, transformation single device
annual fixation volume We to needs our to and physician over have clinical Complementary X.X penetration across unmet procedures, deliver sacropelvic the allowed years. identifying record with markets doubled deeper and average in large growth markets X target procedure a successfully us total driven developing proven last percent new track pelvic conditions. trauma XX-plus of approximately revenue and million have
in as our profitability on progress we XX% dramatic EBITDA. delivered goals made also the our in a improvement We quarter adjusted
adjusted EBITDA points percentage achieved margin. of last the improvement X years, we've Over over in XX
corporate business, operating growth, hybrid increasing model revenue use of and leverage significant driven scalable to continue commercial by our strong We in achieve the our infrastructure.
we expect procedure business, and Given second in the growth across spine volume tailwinds our driven fixation to interventional growth the across revenue durability accelerate our for pelvic in SI physician all in half, solutions. for markets, continued the growth dysfunction acceleration our and demand surgeons by of the joint
growth XXXX. translate We self-fund future us this with model the as flexibility in our line adjusted to give capital in our positive combined top inflection our adjusted quarter fourth This solid profitability as growth. EBITDA well to expect will EBITDA the liquidity, our of to efficient
revenue also growth large in the and sustainable and numerous positioned the markets sacropelvic to going capture We're space deliver forward. profitable
provide to our me let initiatives key long-term update create on leadership, our extend value. an look as Now we and shareholder drive growth,
territory supported ended the and case with specialists support third-party We clinical quarter agents managers, for infrastructure. sales by with XX Starting coverage.
drove Our XX to increase our million. a hybrid record revenue XX% a territory $X.X in months trailing strategy commercial per
is distributors, portfolio expressed attracting large regional interest agency attention differentiated of building in multiple have who the partnerships. Our
continue trauma agent to We primarily our network, expand public fixation for and opportunities.
plan the to of we us more incremental business. we to allowing expansion The agent is our managers provide expand to density highest physician operating territory base. additional strategically and well also ensure users through quality of the service user selectively as reach network growing hire Concurrently, our physicians leverage in that as can and drive and our
type double-digit to exited The the we've seen synergistic than quarter, quarter last portfolio. one growth. our growth the one solutions in more nature X the second of Moving procedural We with highlights XX% representing engagement. our In more physicians is than continuation active the This active a physicians, physician in active the of use more than on X,XXX years. offer. we the XX% in increase XX% the of of procedure, physicians of performing active of number users
to the solution, X.X for which a our for We procedures, demand deformity momentum leading of With productivity. of platform account the sustained engagement launch deeper physicians. procedure procedures physician. is spine both now and a indicator have drive active portion more interest a significant Granite This volumes and degenerative we're positive cross-portfolio targeting and increasingly of per
translates X,XXX of physicians the training number growing in total fellows the of understand residents residents to the and over Moving academic residents now and second program. using We're followed. into trends and disorders the effort sacropelvic incidence and XX adoption and a trained number our interest diagnosis trained options We of to the quarter, treatment This elevated XXXX. trained in bringing have follows trained encouraged by previously our technologies. who by since
adoption previously XX%. In XXXX, half resulted and to trained residents growing first in of from sustained group follows, the revenue attributable this
Turning clinical evidence. to products and
to define outcomes products evidence. offering continue by fixation We pelvic by markets public in patient backed to care improving reinforce joint our advancing differentiated clinical the SI commitment medical dysfunction and and trauma
points, prior showed the for pain decreased sustained outcome fusion improvement The scores percentage opioids by response XX X using clinical XX% measures, people on finalized score our data baseline, immediate points. of studies. joint with in recently iFuse-XD. years. SALLY, SI We our indicated X-year to disability by market at that to consistent and prospective at The XX all study The the joint trial improved fusion iFuse-XD from patient with XX% follow-up clinical first while improved SI
The physical function long-term positive test baseline showed joint analysis XXX% the from of persistent rate fusion. and radiographic with improvement was
have driving migrated from the original to faster fusion. physicians fenestrated porosity fixation Our iFuse and design, better to iFuse-XD and due and
entirety of volume active trauma our a to across and to titanium strategy. building on and iFuse-XD is our and has the Spine iFuse-TORQ through growth almost be success for continues triangular physician procedure and accounts SI pelvic the both cornerstone engagement Interventional of revenue XXXX. been implant key joint engagement iFuse-XD of a patented contributor dysfunction
The on in XXXXX]. utilized comprehensive our CPX efficacy fusion provide seeing majority both recently under we of cases the Pain the Interim Annual performed transfixing multi-center in early growing reimbursed lateral results, SI by of and and iFuse-TORQ with the prospective performed STACI in Neuroscience second Miami, of While Meeting is study. interventionalists in Society [ a of code transfixing iFuse-INTRA interventionalists we're safety the presented which quarter, iFuse-TORQ, adopting at which outcomes by were lateral confirm training interventionalists. joint aligns when the the interventional iFuse-TORQ trajectory, American and confidence
The effectiveness Michael joint fusion Jon reported Pain lateral Wisconsin a studies observed of a iFuse-TORQ. XX% SI And Research average follow-up, an position lateral the Dr. those commensurate published of the and procedure was in publication pain. XX with Spine in leading improvement interventional the XX% Journal joint year. and recent meta-analysis at confirmed his by a safety at from lateral of Jen, Dr. of of Pain. were also in results least of patients with cases last using months iFuse-TORQ The of first fusion published X SI outcomes large spine in
highlighted construct our to foundation procedures of provide need customers become Since the its standard increasing of one a still at the in that seen base demand, launch the for a of rapid the adoption. innovative Even and in surgery. Granite iFuse by with long of products believe SI will unmet We has underpenetrated the clear fixation strong large spine a joint and clinical has Bedrock most durable opportunity. rapidly Granite addressing infusion have XXXX, been care we as
annual have expressed allow diameter Granite points will replacement pelvic It believe approximately has fixation. including surgeons launched X to application will Granite of for In us address broader category this also lumbar quarter, in X.X smaller target found implant X shorter, who in X the for pedicle, lumbar specific procedures. that we of enable best-in-class an procedures. significant better fusion Granite the level shorter needs second preference the SX engage the also procedures. to fusion to We XXX,XXX length offering to provide deformity a of additional X.X, appropriate
been The reception has X.X Granite spectacular. for
product Looking market. in beginning of fourth of a months ahead, we will products the have pelvic specifically quarter and be [indiscernible] that the launched with active targeting the coming pipeline differentiated years, launch an
performance, update me Directors. our additions Anshul of let Before financial the provide quick to our Board recent discusses a on
Medtronic. our the Wolfe Thomas medical physicians. our XX, privately Meeting. Johnson Tom to the career Annual Left company physician at was his to its June built On with nerve CEO Johnson Today, Intersect device up primarily of ENT, pain shareholders a and a currently and recently positions Dan Stockholder Directors of President Board by the Dan of operational strategic interventional announced is and medical surgery increasing elected management held spine also development Board lead and Chief selling of our the Nalu Hologic in Tom Medtronic to of appointment acquisition experience a Strategy CEO Senior Medicrea. peripheral to of is stimulation, with our business of and Medical, pain including and of we device our International. personalized in across push operational bring Officer additions tremendous surgery to of leadership M&A at and Medtronic's Dan responsibility Tom held Previously, spine and Directors. Board. the interventional great Baxter and are Dan Vice mix and at & acquisition
over I'll the that, call With to hand Anshul.
